Jeffrey L Dage, Ani Eloyan, Maryanne Thangarajah, Dustin B Hammers, Anne M Fagan, Julia D Gray, Suzanne E Schindler, Casey Snoddy, Kelly N H Nudelman, Kelley M Faber, Tatiana Foroud, Paul Aisen, Percy Griffin, Lea T Grinberg, Leonardo Iaccarino, Kala Kirby, Joel Kramer, Robert Koeppe, Walter A Kukull, Renaud La Joie, Nidhi S Mundada, Melissa E Murray, Malia Rumbaugh, David N Soleimani-Meigooni, Arthur W Toga, Alexandra Touroutoglou, Prashanthi Vemuri, Alireza Atri, Laurel A Beckett, Gregory S Day, Neill R Graff-Radford, Ranjan Duara, Lawrence S Honig, David T Jones, Joseph C Masdeu, Mario F Mendez, Erik Musiek, Chiadi U Onyike, Meghan Riddle, Emily Rogalski, Stephen Salloway, Sharon J Sha, Raymond S Turner, Thomas S Wingo, David A Wolk, Kyle B Womack, Maria C Carrillo, Bradford C Dickerson, Gil D Rabinovici, Liana G Apostolova
INTRODUCTION: One goal of the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) is to define the fluid biomarker characteristics of early-onset Alzheimer's disease (EOAD). METHODS: Cerebrospinal fluid (CSF) concentrations of Aβ1-40, Aβ1-42, total tau (tTau), pTau181, VILIP-1, SNAP-25, neurogranin (Ng), neurofilament light chain (NfL), and YKL-40 were measured by immunoassay in 165 LEADS participants. The associations of biomarker concentrations with diagnostic group and standard cognitive tests were evaluated...
July 25, 2023: Alzheimer's & Dementia: the Journal of the Alzheimer's Association